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Abstract
Background: Urinary tract infections (UTIs) are common in individuals with neurogenic lower urinary tract
dysfunction (NLUTD) following spinal cord injury (SCI). They are not only a great burden for affected individuals, but
also cause considerable health costs. Furthermore, recurrent antibiotic treatments of UTIs contribute to the growing
problem of bacterial resistance to antimicrobial compounds. Even though there is a multitude of different measures
to prevent UTIs in individuals with NLUTD, no clear evidence exists for any of these. Oral immunomodulation with
UTI-relevant Escherichia coli lysate may be a promising preventative measure with a good safety profile in
individuals with NLUTD. However, currently available data are sparse.
Methods: This is a randomized, quasi-blinded, placebo-controlled, mono-centric pilot trial investigating the
feasibility of a main trial regarding the effects of a lyophilized lysate of E. coli strains for oral application (Uro-
Vaxom®, OM Pharma SA, Meyrin, Switzerland). There will be two parallel groups of 12 participants each. Individuals
with acute SCI (duration SCI ≤ 56 days) from 18 to 70 years of age admitted for primary rehabilitation will be
eligible. Blood and urine samples will be taken prior to intervention start, at the end of the intervention, and 3
months after intervention termination. The trial intervention will last 90 days. The participants will not be informed
regarding the treatment allocation (quasi-blinded). The nursing staff will prepare the daily dose of the allocated
treatment from the original packaging. The trial personnel and the biostatistician will be blinded. Feasibility (e.g.,
recruitment rate, patient attrition), clinical (e.g., number of symptomatic UTIs), and laboratory parameters (e.g.,
urinary culture, urinary proteo- and microbiome, blood cell counts) as well as adverse events will be collected.
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Discussion: Effective and efficient measures for the prevention of UTIs in individuals with NLUTD are urgently
needed. If the conclusion of this pilot is positive regarding feasibility, the effects of oral immunomodulation with a
E. coli lysate will be investigated in a larger, sufficiently powered, multi-center trial.
Trial registration: ClinicalTrials.gov NCT04049994. Registered on 8 August 2019
Keywords: Spinal cord injury, Neurogenic lower urinary tract dysfunction, Urinary tract infection, Escherichia coli,
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Introduction
Background and rationale {6a}
Urinary tract infections (UTIs) continue to be one of the
most common secondary complications in individuals
with neurogenic lower urinary tract dysfunction (NLUTD)
as a result of spinal cord injury (SCI) [1, 2]. The main
contributors to the increased risk of UTI in these
individuals are impaired urine storage and voiding
function, the use of catheters, and a premature onset of
immuno-depression [3–6]. Recurrent UTIs do not only
entail considerable health costs, but also decreased quality
of life [7, 8]. Furthermore, increased bacterial resistance to
antimicrobial compounds as a result of repeated antibiotic
treatments of UTIs is a major concern [9].
Apart from optimizing lower urinary tract function and
removing morphologic causes of infection (i.e., bladder
stones) [10], different remedies, such as phytotherapeutics,
urine acidifiers, and antiseptic substances, are frequently
applied in order to prevent UTIs in individuals with
NLUTD [5]. However, there is still no clear evidence for
an effect of these therapies [10]. In women without
NLUTD, oral immunomodulation with a lysate of UTI-
relevant Escherichia coli appears to be effective in the pre-
vention of UTIs. The intervention resulted in a signifi-
cantly lower UTI rate and use of antibiotics compared to
placebo [11, 12]. Immunomodulation with E. coli fractions
may also be a promising preventative measure in individ-
uals with NLUTD. However, currently available data are
sparse and limited as a result of evaluating clinically not
relevant outcome measures (i.e., presence of bacteriuria)
[13] or the nature of the investigations (i.e., retrospective
[14]/feasibility study [15]). Oral immunomodulation with
a E. coli lysate shows a good safety profile [11, 12, 15], and
thus, its efficacy in individuals with NLUTD should be
investigated.
Objectives {7}
The primary objective of this pilot trial is to evaluate the
feasibility of a main trial. The secondary objective is to
collect data for an informed sample size calculation. A
further objective is to investigate the clinical (number of
symptomatic UTI), biological (stimulation of the
immune system), and urinary microbiome changes after
immunomodulation.
Trial design {8}
This is a randomized, placebo-controlled, mono-centric
pilot trial with two parallel groups of 12 trial participants
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each (1:1 allocation). Allocation will be determined by
block-randomization stratified according to sex. The rea-
son for stratification according to sex is the higher risk
of UTIs in women with SCI [16]. Trial participants will
receive the intervention for 90 days and will be followed
up for 3 months thereafter.
Methods: participants, interventions, and
outcomes
Study setting {9}
The trial is embedded within the Swiss Spinal Cord Injury
Cohort Study (SwiSCI) as a Nested Project and benefits
from the services of the SwiSCI Biobank. We decided to
run this trial in a single center, because the primary
objective is to evaluate the feasibility of a main trial. The
trial center is with 206 beds the largest rehabilitation and
acute care center specialized in SCI in Switzerland.
Eligibility criteria {10}
Individuals with acute SCI (duration SCI ≤ 56 days)
from 18 to 70 years of age during primary rehabilitation
(hospitalization at least until termination of trial
intervention) are eligible for the trial. The onset of SCI
has to have occurred within 72 h. Eligible patients need
to consent to participation in the SwiSCI cohort study
prior to consenting to the present trial. The presence of
any one of the following criteria will lead to the
exclusion of an individual or trial participant:
– Bladder evacuation by permanent transurethral
catheterization at the trial start
– Known hypersensitivity to investigational product or
placebo (galactose, fructose, lactose)
– Any other therapies for preventing UTIs (e.g., urine
acidification, phytotherapy)
– Immunomodulation (apart from routine
vaccinations)
– Immunosuppressant therapy
– Oncological or autoimmune disease
– Diabetes mellitus, nephropathy, bladder stones
– Chronic bacterial prostatitis, recurrent UTIs prior to
SCI
– Women who are pregnant or breastfeeding
– Drug or alcohol abuse
– Suspected inability to follow the procedures of the
trial (e.g., language problems, psychological
disorders, dementia)
– Participation in an interventional trial affecting the
urinary tract or immune system during and within
the 30 days preceding the present trial
Who will take informed consent? {26a}
Investigators who are board-certified neuro-urologists
will inform eligible patients about the trial and request
them to read the trial information. The ethics committee
of Northwestern and Central Switzerland (Project ID
2019-01768; final approval 26.11.2019) has approved the
written trial information and consent form. The written
informed consent will be obtained not earlier than 24h
after the initial oral information. Eligible patients will
have the opportunity to ask questions regarding the trial.
There will be no monetary or other compensation for
trial participation.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Potential trial participants will be asked to give
additional consent for the use of the personal health
data and biological specimens collected during the trial
in future clinical research projects.
Interventions
Explanation for the choice of comparators {6b}
The active intervention has been approved in
Switzerland for the prevention of recurrent infections of
the lower urinary tract and as an auxiliary treatment of
acute UTIs. Placebo is the standard comparator in
clinical trials investigating the effect of a medicinal
product, if placebo treatment is ethically justifiable. In
the present trial, participants allocated to the placebo
group will not incur any disadvantages, because the trial
protocol does not prevent standard clinical treatment of
UTIs with antibiotics. The effectiveness of Uro-Vaxom®
has not yet been established in individuals with SCI, and
participants allocated to the placebo group may receive
Uro-Vaxom® treatment after trial termination.
Intervention description {11a}
Experimental group
Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a
lyophilized lysate of 18 E. coli strains (6 mg) for oral
application. The treatment will last 90 days (one capsule
daily). The dose and duration of the experimental
treatment have been chosen according to the medicinal
product package leaflet.
Control group
Off-the-shelf placebo tablets (P-Dragees, Zentiva Pharma
GmbH, Germany) will be used as control treatment.
According to the treatment regimen of the experimental
group, trial participants in the control group will receive
one sugar-coated tablet daily for 90 days.
Criteria for discontinuing or modifying allocated
interventions {11b}
Allocated treatments will not be modified. The criteria
for discontinuation of the interventions are informed
consent withdrawal, an intervention-related serious
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adverse event (SAE), or the presence of a listed exclusion
criterion.
Strategies to improve adherence to interventions {11c}
In-house patients during primary rehabilitation will be
enrolled. Trial participants will remain hospitalized for
the entire duration of the trial intervention (see
eligibility criteria). The nursing staff will prepare the trial
drug or placebo daily and monitor the ingestion. Any
failure to ingest the trial drug or placebo will be
documented and reported to the principal investigator.
The trial coordinator will monitor the reporting and
documentation of UTIs (symptoms, laboratory results)
and their treatment in trial-specific case report forms
(CRFs). If trial participants get discharged from primary
rehabilitation prior to trial termination and do not re-
turn the CRFs regarding UTIs, the trial coordinator will
collect the required data during telephone interviews.
Relevant concomitant care permitted or prohibited
during the trial {11d}
Standard clinical treatment of acute UTIs (i.e.,
antibiotics, bladder irrigation) will be permitted.
However, other measures to prevent the occurrence of
UTIs (e.g., urine acidification or phytotherapy) will not
be permitted. According to evidence-based medicine cri-
teria, none of the currently applied prophylactic mea-
sures can be recommended.
Provisions for post-trial care {30}
There are no provisions for post-trial care, as there is no
risk of harm as a result of the trial intervention after
intervention termination and beyond follow-up period.
Outcomes {12}
Primary outcome
The randomization rate will be determined by
calculating the proportion of eligible patients who are
enrolled and randomized during the trial.
Secondary outcomes: feasibility
– Positive screening rate: proportion of screened
patients who are eligible
– Recruitment rate: proportion of eligible patients who
gave consent
– Treatment-specific retention rates: proportion of
randomized trial participants in each treatment arm
who finish the trial
– Treatment-specific adherence rate: proportion of
trial participants allocated to a treatment arm who
complete (≥60 capsules/tablets taken) the treatment
– Reasons for premature trial termination
– Assessment completion rate: proportion of planned
assessments that are completed
Secondary outcomes: clinical measures
– UTI symptoms during the treatment and the follow-
up period: self-report questionnaire completed fort-
nightly (new/increased incontinence/leaking or in-
creased urgency or increased catheterization
frequency, fever/chills, increase in spasticity, malaise
or feeling sick or fatigue, cloudy and foul-smelling
urine, bladder or lower back pain or pain during
urination, new/increased occurrence of goosebumps
or sweating)
– Urine analysis (at baseline, treatment end, trial end,
and if clinically indicated): leucocytes, nitrite, pH,
protein, blood determined by dip stick, and
leucocyte count in sediment
– Urine culture results (if clinically indicated):
bacterial species, colony-forming units (cfu), and
antibiotic resistance
– UTI count: an event is counted as a UTI if ≥10,000
cfu/ml and a positive urine analysis result
(leucocytes, nitrite) are present
– Urinary microbiome (at baseline, treatment end,
trial end)
– Urinary proteome/transcriptome (at baseline,
treatment end, trial end): cytokines, immunoglobulin
(Ig)A levels
– Blood cell count (at baseline, treatment end, trial
end): leucocytes, erythrocytes, hemoglobin,
hematocrit, mean corpuscular volume, mean
corpuscular hemoglobin, mean corpuscular
hemoglobin volume, and platelets
– White blood cell differential (at baseline,
treatment end, trial end): granulocytes,
neutrophils, eosinophils, basophils, monocytes,
and lymphocytes
– Side effects: self-report questionnaire completed
fortnightly during the treatment period
Other outcomes of interest
– Patient characteristics: age, sex, lesion level,
American Spinal Injury Association impairment
scale (AIS), duration SCI, and etiology SCI
– Bladder evacuation method
– Concurrent medication
– Medical history: infections, urinary tract disease, and
surgery
– Self-report questionnaire trial end: trial experience
(burden trial medication, burden questionnaire
completion, “would you participate again?,” would
you recommend trial participation?”), satisfaction
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with treatment effect and assumption regarding
treatment allocation
Participant timeline {13}
The schedule of enrolment, interventions,
assessments, and visits for participants is shown in
Fig. 1. Eligible patients will be approached regarding
trial participation after admission for primary
rehabilitation as soon as their physical and mental
condition allows. The trial intervention will
commence not later than 56 days after SCI has
occurred. Prior to intervention start, blood and urine
samples will be taken as well as at the end of the
intervention and 3 months after intervention
termination (Fig. 1). The trial intervention will last 90
days. During the intervention and follow-up period (3
months), the occurrence of UTIs, symptoms, and
treatment will be recorded. At the trial end, partici-
pants will fill out a questionnaire regarding their ex-
periences during the course of the trial. In
participants who prematurely stop the trial, a safety
follow-up period of 7 days will be observed to moni-
tor the occurrence of SAEs.
Sample size {14}
A total of 24 participants will be included based on the
rule of thumb of 12 participants per treatment arm in
pilot studies suggested by Julious and Owen [17]. The
sample size will be sufficient to evaluate the feasibility of
a main trial which is the primary objective of this pilot
trial. If more than 6 participants in a treatment arm
terminate the trial prematurely, additional participants
will be recruited until at least 6 have completed the trial
protocol.
Recruitment {15}
All patients with acute SCI admitted for primary
rehabilitation will be screened for inclusion and
exclusion criteria by authorized trial staff.
Fig. 1 Schedule of enrolment, interventions, and assessments. UTIs urinary tract infections
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Assignment of interventions: allocation
Sequence generation {16a}
The allocation sequence was generated stratified
according to sex, with a 1:1 allocation ratio and variable
block sizes using the R software environment (version
3.6.0, Copyright 2019, The R Foundation for Statistical
Computing) and the package “blockrand.” The allocation
list contains 20 male and 12 female participants.
Concealment mechanism {16b}
The allocation list has been imported into the trial
database. Upon registration of a new trial participant in
the database, a sequential number will be allocated for
each stratum separately. The hospital pharmacy keeps
the list linking the allocation number with the treatment
arm (A or B) and will deliver the allocated treatment to
the ward. The trial personnel has no access to the list.
The biostatistician will receive the blinded treatment
allocation (A or B) list when data collection will have
been completed. Furthermore, the laboratory personnel
will be informed concerning the blinded treatment
allocation, in order to ensure balance between allocation
groups for the analysis of a specific batch of samples and
thus avoid a batch effect.
Implementation {16c}
A biostatistician of the Swiss Paraplegic Centre Clinical
Trial Unit (CTU) has generated the allocation sequence.
Authorized trial personnel will register participants in
the trial database and inform the head of the hospital
pharmacy regarding the allocation number. The head of
the pharmacy will assign participants to treatments
based on the allocation list.
Assignment of interventions: blinding
Who will be blinded {17a}
The trial interventions (Uro-Vaxom® and placebo) will
be delivered to the ward within the original packaging
supplied by the hospital pharmacy. The trial
medication will be personalized and labeled for each
study participant. The nursing staff will daily prepare
a single dose of the allocated treatment (removing
capsule or tablet from blister or container).
Preparation and administration of the trial medication
will follow the study working instruction, will be
overseen by nursing experts, and will be recorded in
the hospital information system. Trial participants will
not be informed regarding the treatment allocation.
The trial treatment will be prescribed as “Uro-Vax
trial medication” in the electronic medical records
system. The trial personnel (outcome assessors) and
biostatistician will be blinded regarding treatment
allocation.
Procedure for unblinding if needed {17b}
Unblinding will be permissible in the occurrence of a
SAE. A code break is not required because the nursing
staff is not blinded to the treatment arm. Furthermore,
unblinding will be performed after having completed all
data analyses.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Feasibility outcomes
An electronic list (Microsoft Excel 2016) of all screened
patients will be maintained, and information regarding
eligibility, exclusion criteria, and enrolment will be
collected. Additionally, a paper (p)CRF regarding all
inclusion and exclusion criteria will be completed before
enrolment. Exclusion criteria will also be recorded on a
pCRF fortnightly during the intervention period as well
as at the end of the intervention and follow-up period.
Any premature trial termination and the reasons will be
documented in an electronic (e)CRF of the trial data-
base. Furthermore, the number of ingested trial medica-
tion (capsules/tablets) will be documented in an eCRF.
Clinical outcomes
During the intervention period, trial participants will
complete a self-developed paper questionnaire regarding
UTI symptoms and treatment side effects every 2 weeks.
The following UTI symptoms are listed: fever/shivering;
new or increased urinary incontinence/leaking, increased
urgency, increased catheterization frequency; increased
spasticity; malaise, feeling sick, fatigue; cloudy, foul-
smelling urine; abdominal/lower back/kidney pain, pain
during bladder voiding; and goose bumps, increased
sweating. Participants have the possibility to list any
other symptoms experienced. An event is counted as a
symptomatic UTI if at least one bladder symptom (new
or increased urinary incontinence/leaking, increased ur-
gency, increased catheterization frequency, pain during
bladder voiding) and another symptom have been re-
ported together with a positive urine analysis result (leu-
cocytes, nitrite) and a growth of ≥10,000 cfu/ml in the
urine culture (sample collected by via naturalis).
The following side effects are listed: headache,
abdominal pain, nausea, vomiting, diarrhea, and
heartburn. Participants have the possibility to list any
other side effects experienced. In the event of a
symptomatic UTI, data from clinical routine assessments
(i.e., urinary status and urine culture results) and the
chosen treatment will be collected from the electronic
medical chart file and recorded in an eCRF.
During the follow-up period, trial participants will
complete a self-developed paper questionnaire regarding
UTI symptoms (same as above), assessments (dip stick
and urine culture), and treatment fortnightly. In the
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event of a symptomatic UTI in still hospitalized trial par-
ticipants, data from clinical routine assessments (i.e.,
urinary status and urine culture results) and the chosen
treatment will be collected from the electronic medical
chart file and recorded in an eCRF.
Biological outcomes
At the three assessment time points (baseline, treatment
end, trial end), urine (30ml) and blood samples (30ml)
will be taken. The urinary status, proteome and
transcriptome, microbiome, and the standard blood cell
count and white blood cell differential will be evaluated.
In order to assess the urinary microbiome, urine will
be cultured using a streamlined enhanced quantitative
urine culture described by Price et al. [18]. Microbial
identification will be performed using matrix-assisted
laser desorption/ionization–time-of-flight mass spec-
trometry (MALDI-TOF MS; Bruker Daltonics, Billerica,
MA, USA) of distinct colonies. The colony morphology
will be described and quantified. Furthermore, within 4h
of collection, urine will be spun at 3000rpm, and the
resulting pellet will be suspended in 1ml urine for stor-
age at − 80°C until deoxyribonucleic acid (DNA) extrac-
tion. The DNA extraction will be accomplished using the
QIAamp PowerFecal DNA kit (QIAGEN, Hilden, Germany)
according to the manufacturer’s protocol. Whole genome
(sufficient quantity of genomic DNA extracted) or 16S se-
quencing (smaller quantity of DNA extracted) will be per-
formed using the MinION nanopore sequencer (Oxford
Nanopore Technologies, Oxford, UK). Sequencing libraries
will be prepared using the Nanopore Ligation Sequencing
Kit (Oxford Nanopore, Oxford, UK) and sequenced with the
MinION flow cell using a high accuracy model. Bioinformat-
ics analysis will use the FASTQWIMP (“What’s In My Pot”)
(Oxford Nanopore, Oxford, UK) analysis workflow validated
for microbiome analysis.
In order to assess the relevant proteins of the urinary
proteome and transcriptome, we will use two sample
types: (1) centrifuged and sterile filtered (0.22μm) urine
and (2) urine pellets (where present). These samples will
be analyzed by enzyme-linked immunosorbent assay
(ELISA) for total quantity of IgA antibodies and quantity
of IgA antibodies against the E. coli lysate included in
Uro-Vaxom®. The quantity of pro- and anti-
inflammatory cytokines such as interferon (IFN)-γ,
tumor necrosis factor (TNF)-α, tumor growth factor
(TGF)-β, and interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6,
IL-8, IL-10, IL-13 will be determined using ELISA and
reverse transcription polymerase chain reaction (RT-
PCR) arrays of extracted ribonucleic acid (RNA).
Other outcomes of interest
Patient characteristics, bladder evacuation method, and
concurrent medication will be collected from the
electronic medical chart file and recorded in an eCRF.
Data regarding the medical history will be collected
using a pCRF. At the end of the follow-up period, partic-
ipants will fill out a self-developed pCRF regarding their
experiences, treatment satisfaction, and assumption re-
garding treatment allocation.
Plans to promote participant retention and complete
follow-up {18b}
Trial participants will remain hospitalized during the
treatment period (see eligibility criteria). If a trial
participant is discharged before completion of the trial,
telephone interviews will be planned to collect outcome
measures regarding UTIs, in case the participant does
not return the self-report questionnaires.
In participants who discontinue or deviate from
intervention protocols, all outcome data as per protocol
will be collected as long as participants stay in the trial.
In case of premature trial termination, clinical routine
data regarding UTIs will be collected, if participants
have not rejected the use of health-related data and sam-
ples for research purposes (general consent).
Data management {19}
Trial source data will be recorded in pCRFs or directly
in eCRFs (see above). All data will be recorded
encrypted. Trial data from pCRFs will be transferred to
eCRFs in a timely manner. The eCRFs will be kept
current to reflect the participant’s status during the
course of the trial. The eCRFs have been created in the
web-based data management system secuTrial® (iAS,
Berlin, Germany). The system is hosted on a secure in-
house server. Only trained and authorized trial
personnel will enter data into the electronic database.
Prior to the release into the productive environment,
the electronic trial database has been tested by the data
manager and one investigator. Specific definitions of
data entry fields as well as range and consistency checks
for entered data values will promote data quality.
Furthermore, a monitoring plan (see below) is set up to
ensure that the entered data values are accurate. All
entered data will be reviewed and verified by an
investigator and signed-off by the principal investigator
prior to data export for analyses in statistical software.
The biological data derived from the encrypted
samples will be stored on a secure server of the hospital.
Data will only be accessible by members of the trial
team.
Confidentiality {27}
The investigators affirm and uphold the principle of the
participant’s right to privacy and will comply with the
applicable privacy laws. The anonymity of the
participants will be guaranteed when presenting the data
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at scientific meetings or publishing them in scientific
journals. Individual medical information obtained as a
result of this trial will be considered confidential and
will not be disclosed to third parties. Direct access to
not encrypted source documents will be permitted for
authorized third parties for purposes of monitoring,
audits, and inspections. The trial staff will have access to
the trial data based on authorization by the principal
investigator. Confidentiality will be established by
utilizing identification codes to link participants with
trial data. The identification codes will not contain
name, initials, date of birth, or any other personal
identification numbers (e.g., social security number,
patient identification number, etc.). The list with the
assigned trial identification codes and minimal personal
information (i.e., name, date of birth) will be stored in a
locked cabinet at the trial site. All CRFs and data
collection files will be identified with the trial code only.
After trial closure, all trial data will be stored in a locked
archive room with limited access for 10 years.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
All processing of biological specimens will be done with
encrypted samples (blood and urine). The samples from
each assessment time point will be transferred for
processing to the SwiSCI Biobank, which has been
audited and certified by the Swiss Biobanking Platform
(SBP). The processing of the samples will be done
preferably by a team of two persons (preferably)
according to validated workflows and SOPs, starting
with the most perishable sample (urine), in order to
ensure the shortest possible processing (needle-to-
freezer) time. A biobanking software (FreezerPro Brooks,
Chelmsford, MA, USA) will be used for documentation
as well as sample and aliquot tracking. Samples will be
accessed and withdrawn according to validated
procedures and analyzed according to the trial protocol.
Any unused samples will be stored for at least 5 years
after the end of the trial.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
All the data of randomized trial participants will be
analyzed blinded and according to an intention-to-
treat basis. This is a feasibility trial, and thus, de-
scriptive statistics will be used. All outcome mea-
sures will be presented as point estimates and 95%
confidence intervals. Differences in clinical and la-
boratory outcome measures between the two treat-
ment groups will be evaluated based on confidence
intervals.
Interim analyses {21b}
This is a feasibility trial, and thus, no interim analyses
will be performed.
Methods for additional analyses (e.g., subgroup analyses)
{20b}
This is a feasibility trial, and thus, there will be no
subgroup analyses.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
All available data will be included for intention-to-treat
analysis. Missing data will not be imputed.
Plans to give access to the full protocol, participant-level
data, and statistical code {31c}
Access to the full protocol, participant-level data, and
statistical code will be given upon reasonable request to
the corresponding author.
Oversight and monitoring
Composition of the coordinating center and trial steering
committee {5d}
There is no coordinating center or trial steering
committee.
Composition of the data monitoring committee, its role,
and reporting structure {21a}
This is a mono-centric pilot trial evaluating the feasibil-
ity of a main trial investigating an approved medicinal
product with a low-risk profile. Thus, there is no data
monitoring committee.
Adverse event reporting and harms {22}
Treatment side effects are collected from self-report
questionnaires fortnightly during the treatment period.
All SAEs are collected and documented from the start
of the trial treatment until 7 days after completing or
terminating the treatment (safety follow-up time). Any
suspected unexpected (not consistent with product in-
formation) serious adverse reaction (SUSAR) will be re-
ported to the ethics committee within 15 days (events
resulting in death within 7 days) of becoming aware of
the event.
Frequency and plans for auditing trial conduct {23}
An independent monitor from the CTU of the Swiss
Paraplegic Centre will verify that the rights and well-
being of the trial participants are protected; that the col-
lected data are accurate, complete, and verifiable from
source documents; and that the conduct of the trial
complies with the currently approved protocol, the
International Council for Harmonisation E6(R2) Good
Clinical Practice Guideline, and the applicable regulatory
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requirements. Monitoring will be performed according
to the monitoring plan (version 1.1 dated 18.11.2019)
developed for the trial (Supplement 1).
Plans for communicating important protocol
amendments to relevant parties (e.g., trial participants,
ethical committees) {25}
Substantial amendments are submitted to the ethics
committee for approval before implementation. In
emergency circumstances, deviations from the protocol
to protect the rights, safety, and well-being of trial par-
ticipants will proceed without prior approval by the eth-
ics committee. However, these deviations and measures
will be documented and reported to the ethics commit-
tee within 7 days. Active trial participants will be in-
formed regarding all relevant protocol amendments
concerning their rights, safety, and well-being.
All non-substantial amendments are communicated to
the ethics committee within the annual safety report.
Dissemination plans {31a}
The data from the present trial will be presented at
scientific meetings and published in peer-reviewed jour-
nals. The authorship will be determined based on the
contributions of the individuals involved.
Discussion
Due to the lack of evidence, a plethora of measures and
treatments are currently applied to prevent UTIs in
individuals with NLUTD. Specific measures are chosen
and combined according to personal convictions or
preferences and mainly aim at preventing infections with
E. coli, which is the most commonly detected
microorganism in UTIs in these patients [19]. Oral
immunomodulation with a lysate of UTI-relevant E. coli
is thus a promising preventative measure against E. coli
UTI, but the evidence is lacking, too. Furthermore, there
are preliminary observations that immunomodulation
with a E. coli lysate may also be beneficial in UTI caused
by other bacteria [14]. However, there is a lack of data
from randomized placebo-controlled trials with clinically
relevant outcome measures.
Overly optimistic forecasts regarding eligibility and
enrollment rates, overly strict eligibility criteria,
competition with other trials, and undue patient burden
are major reasons why too many trials either require
more time to complete recruitment goals or fail to
enroll the targeted number of participants [20]. A
realistic estimation of the enrollment rate at a trial
center is crucial for planning a successful trial and
requires a pilot phase. In order to optimize the
enrollment rate, we have established defined screening
and recruitment procedures and appointed a dedicated
trial coordinator. A trial coordinator helps to prioritize a
trial within the busy clinical routine and will have a
positive effect not only on enrollment, but also on
retention of trial participants [21, 22]. In order to
improve retention further, the trial protocol was drafted
to be in line with the clinical processes at the trial
center. Patients are more inclined to consent to trial
participation if they believe that they will profit, which is
not the case when they are assigned to the placebo
group [23]. Thus, we make sure that patients understand
they will receive standard of care in case of a UTI. Uro-
Vaxom® has a good safety profile [11, 12, 15], and thus,
concerns regarding side effects should not represent a
major issue. Additional tests, depending on the number,
invasiveness, and time requirements, increase the burden
of patients and have a negative effect on enrollment and
retention [20]. We have therefore minimized the burden
of trial assessments. In the present trial, potential partici-
pants are approached within the first 56 days after SCI,
when many still feel overwhelmed by the new life-
changing condition and thus may rather decline partici-
pation than consent [24]. Nevertheless, we have chosen
this population to investigate, whether immunomodula-
tion has an effect during the phase of immuno-
depression shortly after SCI [25] and whether it prevents
bladder colonization with pathogenic bacteria, which is
very common in this population. Furthermore, running
a trial during primary rehabilitation will improve adhe-
sion to trial medication [26] and eliminate the need to
return to the trial center for follow-up evaluations. We
paid special attention to the information and instruction
of the nursing and medical staff, in order to ensure ad-
ministration of the trial drug and reporting of SAEs ac-
cording to the trial protocol. The trial is embedded
within a cohort study and thus benefits from established
screening and sampling processes. However, the require-
ment to first consent to the participation in the cohort
study will preclude some patients from enrolling in the
trial. Apart from enrollment, retention, and adhesion
rates, this pilot trial will also assess other feasibility is-
sues like costs and adequate staffing.
The primary outcome of the future main trial will be
the count of symptomatic UTI during the observation
period. The diagnosis of a clinically relevant UTI in the
chosen population is challenging as a result of the
mediocre reliability of patient-reported UTI symptoms
[27] and the very common presence of bacteriuria [24].
Furthermore, counting symptomatic UTI requiring anti-
biotic treatment in an out-patient setting is affected by
the relatively subjective assessment of involved clini-
cians. The current trial runs in an in-patient setting, and
thus, urine analysis and culture results will be available
to define the occurrence of a UTI.
The unique feature of the present trial is the objective
to evaluate not only the clinical (number of symptomatic
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UTI) effects of immunomodulation, but furthermore to
investigate the biochemical and cellular responses of the
immune system and the effects on the urinary
microbiome. We will investigate whether
immunomodulation with Uro-Vaxom® has the potential
to stimulate a weakened immune system shortly after
SCI, as shown in an animal study [28], and to prevent or
decrease bladder colonization with pathogenic bacteria.
The concealment of group allocation (blinding) from
trial participants and staff is a critical methodologic
feature of a randomized controlled trial. In order to
minimize the costs and administrative hurdles in this
pilot trial, we have chosen not to blind the trial
participants. Trial participants will not be informed
regarding treatment allocation. However, the trial
personnel and the biostatistician will be blinded
regarding treatment allocation. Standard clinical
treatment of UTIs will be permitted. It would be
unethical to withhold antibiotic treatment of acute
symptomatic UTIs from trial participants. Antibiotics
will have an effect on the urinary microbiome and thus
represent a limitation of the present trial.
Trial status
Protocol version 1.3 dated 10.07.2020. Recruitment
began on June 1, 2020, and is expected to be complete
by May 31, 2023.
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